These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 26551625)
1. Overview: A New Era of Cancer Genome in Myeloid Malignancies. Kiyoi H Oncology; 2015; 89 Suppl 1():1-3. PubMed ID: 26551625 [TBL] [Abstract][Full Text] [Related]
2. A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML. Kats LM; Vervoort SJ; Cole R; Rogers AJ; Gregory GP; Vidacs E; Li J; Nagaraja R; Yen KE; Johnstone RW Leukemia; 2017 Jun; 31(6):1466-1470. PubMed ID: 28280273 [No Abstract] [Full Text] [Related]
4. Enasidenib for patients with relapsed acute myeloid leukemia and the IDH2 mutation. DiNardo C Clin Adv Hematol Oncol; 2018 Apr; 16(4):247-249. PubMed ID: 29742078 [No Abstract] [Full Text] [Related]
5. All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells. Kim Y; Jeung HK; Cheong JW; Song J; Bae SH; Lee JI; Min YH Yonsei Med J; 2020 Sep; 61(9):762-773. PubMed ID: 32882760 [TBL] [Abstract][Full Text] [Related]
6. IDH2 inhibition in AML: Finally progress? Stein EM Best Pract Res Clin Haematol; 2015; 28(2-3):112-5. PubMed ID: 26590767 [TBL] [Abstract][Full Text] [Related]
7. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Amatangelo MD; Quek L; Shih A; Stein EM; Roshal M; David MD; Marteyn B; Farnoud NR; de Botton S; Bernard OA; Wu B; Yen KE; Tallman MS; Papaemmanuil E; Penard-Lacronique V; Thakurta A; Vyas P; Levine RL Blood; 2017 Aug; 130(6):732-741. PubMed ID: 28588019 [TBL] [Abstract][Full Text] [Related]
8. Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia. Dogra R; Bhatia R; Shankar R; Bansal P; Rawal RK Anticancer Agents Med Chem; 2018; 18(14):1936-1951. PubMed ID: 30360730 [TBL] [Abstract][Full Text] [Related]
9. Targeting the Amaya ML; Pollyea DA Clin Cancer Res; 2018 Oct; 24(20):4931-4936. PubMed ID: 29769206 [TBL] [Abstract][Full Text] [Related]
10. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. Quek L; David MD; Kennedy A; Metzner M; Amatangelo M; Shih A; Stoilova B; Quivoron C; Heiblig M; Willekens C; Saada V; Alsafadi S; Vijayabaskar MS; Peniket A; Bernard OA; Agresta S; Yen K; MacBeth K; Stein E; Vassiliou GS; Levine R; De Botton S; Thakurta A; Penard-Lacronique V; Vyas P Nat Med; 2018 Aug; 24(8):1167-1177. PubMed ID: 30013198 [TBL] [Abstract][Full Text] [Related]
11. Enasidenib for the treatment of acute myeloid leukemia. Dugan J; Pollyea D Expert Rev Clin Pharmacol; 2018 Aug; 11(8):755-760. PubMed ID: 29770715 [TBL] [Abstract][Full Text] [Related]
12. Enasidenib. Krämer A; Bochtler T Recent Results Cancer Res; 2018; 212():187-197. PubMed ID: 30069631 [TBL] [Abstract][Full Text] [Related]
13. AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic Yen K; Travins J; Wang F; David MD; Artin E; Straley K; Padyana A; Gross S; DeLaBarre B; Tobin E; Chen Y; Nagaraja R; Choe S; Jin L; Konteatis Z; Cianchetta G; Saunders JO; Salituro FG; Quivoron C; Opolon P; Bawa O; Saada V; Paci A; Broutin S; Bernard OA; de Botton S; Marteyn BS; Pilichowska M; Xu Y; Fang C; Jiang F; Wei W; Jin S; Silverman L; Liu W; Yang H; Dang L; Dorsch M; Penard-Lacronique V; Biller SA; Su SM Cancer Discov; 2017 May; 7(5):478-493. PubMed ID: 28193778 [TBL] [Abstract][Full Text] [Related]
14. Novel Therapeutics in Acute Myeloid Leukemia. DiNardo CD; Stone RM; Medeiros BC Am Soc Clin Oncol Educ Book; 2017; 37():495-503. PubMed ID: 28561688 [TBL] [Abstract][Full Text] [Related]